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Abstract
Squamous lung carcinoma lacks specific ‘‘ad hoc’’ therapies. Amplification of chromosome 3q is the most common genomic
aberration and this region harbours genes having role as novel targets for therapeutics. There is no standard definition on
how to score and report 3q amplification. False versus true 3q chromosomal amplification in squamous cell lung carcinoma
may have tremendous impact on trials involving drugs which target DNA zones mapping on 3q. Forty squamous lung
carcinomas were analyzed by FISH to assess chromosome 3q amplification. aCGH was performed as gold-standard to avoid
false positive amplifications. Three clustered patterns of fluorescent signals were observed. Eight cases out of 40 (20%)
showed $8 3q signals. Twenty out of 40 (50%) showed from 3 to 7 signals. The remaining showed two fluorescent signals
(30%). When corrected by whole chromosome 3 signals, only cases with$8 signals maintained a LSI 3q/CEP3 ratio.2. Only
the cases showing 3q amplification by aCGH (+3q25.323q27.3) showed $8 fluorescent signals at FISH evidencing a 3q/3
ratio .2. The remaining cases showed flat genomic portrait at aCGH on chromosome 3. We concluded that: 1) absolute
copy number of 3q chromosomal region may harbour false positive interpretation of 3q amplification in squamous cell
carcinoma; 2) a case results truly ‘‘amplified for chromosome 3q’’ when showing$8 fluorescent 3q signals; 3) trials involving
drugs targeting loci on chromosome 3q in squamous lung carcinoma therapy have to consider false versus true 3q
chromosomal amplification.
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Introduction
Squamous cell cancer accounts for about thirty per cent of lung
cancer [1]. Unlike adenocarcinomas of the lung among which the
increasing genomic characterization has simultaneously led to
increase their biological portrait [1,2,3], squamous cell carcinoma
remains a disease now bereft of a molecular targeted profile. This
leads to consider the need for studies that enhance the molecular
changes that, like EGFR, K-ras and ALK genes for lung
adenocarcinoma, at prognostic and/or predictive levels may give
chances for an effective therapeutic response in these patients [4].
In squamous cell carcinoma amplification of chromosome 3q
region has been observed as the most common genomic aberration
[5]. 3q amplification is important in the tumorigenesis of
squamous cell carcinoma but not necessarily in adenocarcinoma,
thus the 3q amplification itself also represents one of the most
striking sensitive differences between squamous cell carcinoma and
adenocarcinoma of the lung [6,7]. Moreover, in addition to the
diagnostic setting, the 3q region harbors many potential targeted
genes, some of which already showed promising value as
biomarkers in selecting patients for specific drugs, such as anti-
PI3K and -SOX2 targeted therapies [8]. Actually, squamous lung
carcinoma remains a neoplastic tissue orphan of specific ‘‘ad hoc’’
therapies, thus there is a need to identify new molecular and
cytogenetic biomarkers usefull in selecting patients for new drugs
and in designing new clinical trials [9,10].
The interphase in situ hybridization technique is becoming a
routinely available standard molecular assessment requested to
reference Pathology Labs, due i.e. to the value of the Her-2 gene in
breast, gastric cancers, 1p/19q in oligodendrogliomas or EGFRand
ALK genes in lung adenocarcinoma [11,12,13,14,15]. Differently
for the aforementioned biomarker assessment on which standard
guidelines have been proposed, there is no clear definition on how to
analyze analytically 3q chromosomal abnormalities and how to
initially determine and finally score and report 3q amplification.The
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lack of a precise method for calculation may lead to a different
interpretation of signals among different labs and across different
studies; reading and interpreting the ISHassay reinforce the need for
standardised testing procedures. In squamous cell carcinomas, at
both cytogenetic and molecular levels, reports often do not
distinguish chromosomal amplification due to an increase of the
locus specific region 3q (and the degree) or to the entire chromosome
3. Polyploidy and genetic instability may bring false positive
interpretation of 3q amplification.
In the actual study we sought to evaluate the subtypes of
genotypic abnormalities of the entire chromosome 3 and the distal
locus specific 3q that maps the SOX-2 and PI3CA genes in a serie
of squamous lung carcinoma [16,17,18,19,20,21,22,23], by
weighting different chromosomal anomalies mapped by fluores-
cent ISH (FISH) and aCGH front techniques on routinely
available formalin-fixed neoplastic tissue.
Finally, we inizialize a scoring for the assessment of 3q
amplification, in order to provide a tool to support the clinical
laboratories either for the diagnostic goal either for selection to
clinical trials encountering inhibitors targeting the 3q region such
as anti- PI3CA or –SOX2 targeted drugs.
Materials and Methods
Ethic Statements
We used tissue samples from human participants. All tissue
blocks have been previously declaired to be available for the
purposes of the actual study by the Istitutional Review Board
(study conducted according to the principles expressed in the
Declaration of Helsinki). Our institutional review board and the
ethics committee approved the original human work that
produced the tissue samples (Prof. Marco Chilosi, Director of
the Pathology Unit, Azienda Ospedaliera Integrata di Verona,
Verona, Italy and Prof. Aldo Scarpa, Director of the Department
of Pathology and Diagnostic). All processing in obtaining the
material has been performed after a written informed consent.
Full name Ethic/Institutional Review Board: Prof. Marco
Chilosi, Prof. Aldo Scarpa, Prof. Francesco Calabro`, Prof. Guido
Martignoni, Nucleo Ricerca&Innovazione.
Tumour Selection
Fourty squamous lung carcinomas were recruited from the
LUNGVERONADATABASE files, Italy. All samples per tumour
were reviewed by a pathologist expert in the field (MC) and an
appropriate sample containing at least 90%neoplastic cells has been
selected for the interphase cytogenetic and molecular studies.
Immunophenotypical analysis
Immunophenotyping was performed by using Dn-p63 (rabbit,
Oncogene), CK5 (XM26, Novocastra), CK7 (OV-TL12/30,
Biogenex), TTF-1 (8G7G3/1, Dako), Napsin A (TMU-A d02,
Arp), and SOX-2 (rabbit, Seven Hills).
Fluorescence in situ hybridization analysis (FISH) analysis
Interphase cytogenetic fluorescence in situ hybridization anal-
ysis was performed using commercially available telomeric specific
probe (TelVysion 3q, D3S4560) mapping on chromosome 3q
telomere (SpectrumOrange LSI, Vysis-Abbott) and a centromeric
(alpha-satellite DNA, SpectrumGreen) probe mapping on 3p11-
q11. FISH procedure was developed according to previous reports
from our group [24].
5 mm sections were cut from paraffin-embedded blocks. The
procedure of FISH has been performed as detailed in previous
manuscript [24].
Centromeric probes for chromosomes 3 and locus specific
probes for 3q (Vysis-Abbott, Olympus, Rome, Italy) were used.
Each probe was diluted 1:10 in tDenHyb2 buffer (Insitus,
Albuquerque, NM). Ten microliters of diluted probe were applied
to each slide and cover slips were placed over the slides.
Denaturation was achieved by incubating the slides at 80uC for
10 minutes in a humidified box; then hybridization was done at
37uC for 16 hours. The cover slips were then removed and the
slides were immersed at room temperature in 0.5 XSSC for
2 minutes and in 2 XSSC for 2 minutes. The slides were air dried
and counterstained with 10 ml DAPI/Antifade (DAPI in Fluor-
guard, 0.5 mg/ml, Insitus, Albuquerque, NM).
The slides were examined using an Olympus BX61 (Germany)
with appropiate filters for SpectrumOrange (Tel 3q, Vysis-Abbott),
SpectrumGreen (centromeric probe 3, Vysis-Abbott), and the UV
Filter for the DAPI nuclear counterstain. The signals were
recorded with a CCD camera (CytoVysion, Olympus Berlin,
Germany and Fluo/D-SIGHT Menarini/Visia Imaging, Italy).
Fluorescent in situ signals were evaluated on carcinomatous and
normal pulmonary adjacent parenchyma.
Fluorescent 3q signals was initially scored per each case. These
cases were corrected per the score of chromosome 3 signals (LSI
3q/CEP3 .2 ‘‘amplified’’). From 60 to 250 neoplastic nuclei were
assessed per tumours, similarly per adjacent normal parenchyma.
Array CGH and data analysis
Genomic DNA was isolated using QIAamp DNA mini kit
(Qiagen Nordic, Finland) and quantified on the NanoDrop
Spectrophotometer (NanoDrop Technologies Inc., DE, USA).
The quantities and qualities of the DNA allowed us to continue
with the analyses. As reference was used DNA from pooled
peripheral blood leucocytes of healthy males. With Agilent Human
44K array format containing around 44 000 oligonucleotide
probes, covering coding and noncoding genome region (Agilent
Technologies, Santa Clara, CA), we screened for copy number
alteration 6 tumours (2 tumours per each clustered categories
detected at FISH analysis). Briefly, 1.5 mg of tumor and reference
DNA were digested, labeled and hybridized according with the
Agilent Protocols (version 4). The digested DNAs were labeled by
random priming with Cy3-dUTP (reference DNA) and Cy5-
dUTP (patient DNA) by use of the Agilent Labelling Kit, after
which the labelled DNAs were purified. The resolution of the
fragments analyzed varied from several Kb to ,1 Mb depending
upon the case selected.
The array images obtained after scanning (high resolution
Agilent scanner) were processed with the Feature Extraction
software (version 10.5), and the output data files were analyzed
with the Agilent Genomic Workbench. To identify copy number
alterations we used Aberration Detection Method 2 (ADM-2)
algorithm and to exclude the small variances in the data we set up
a custom aberration filter identifying an alterations in copy
number if minimum of 8 probes gained or lost to be present and
with minimum absolute average log ratio for region to be 0.5. The
region with small copy number variations were excluded by
comparing and visualizing the copy number variant regions tool of
the Genomic workbench software.
Results
Tumours
All carcinomas showed pure squamous morphology (Fig. 1a); 11
cases (27,5%) displayed a well, 25 (62,5%) moderate, 4 (10%)
(scarse) degree of differentiation. Thirty carcinomas staged Ia,
eight Ib, one IIa and one IIb.
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Immunophenotypical findings
Immunophenotipically p63 and SOX2 were expressed in all
cases (100%) (respectively Fig. 1b, 1c); 4 cases (11%) expressed
CK7 whereas TTF-1 was always absent. All the cases were also
negative for Napsin A (Fig. 1d).
FISH findings
We observed three clustered patterns of fluorescent signals
(Fig. 4). Eight cases out of 40 (20%) showed $8 (range from 8 to
12, mean 10) 3q signals (range 54%–66%, mean 49% neoplastic
nuclei) (Fig. 2). Twenty out of 40 (50%) showed from 3 to 7 signals
(mean 6) (Fig. 3). The remaining showed two fluorescent signals
per nuclei (30%). When corrected by whole chromosome 3 signals,
only cases with $8 signals maintained a LSI 3q/CEP3 ratio .2.
Overall, FISH findings are summarized in Fig. 4.
Array CGH findings
Among 6 cases tested and focusing on the 3q region, DNA copy
number changes were found in two cases (+3q25.3-q27.3). The
whole aberrations span about 27.5 Mb. Specifically, findings from
oligonucleotide probes spanning the SOX2 and PI3CA zones
revealed more relevant gains for the PA3CA in respect to the
SOX2 zones, although significant differences were not observed.
The remained cases had normal profile. Relevant genomic
abnormalities were observed in three cases (+5p).
When matching cases analyzied by both FISH and aCGH, only
those two cases showing 3q amplification by aCGH scored $8
fluorescent at FISH and evidenced a 3q/CEP3 ratio .2. The
remaining four cases showed a flat genomic profile at aCGH with
focus on the 3q and centromeric regions.
Figure 1. Squamous cell lung carcinoma. Squamous differentiation of cancerous neoplastic cells (a) showing immunoexpression of p63 (b),
SOX2 at nuclear level (c), and absence of Napsin-A (d).
doi:10.1371/journal.pone.0049689.g001
Figure 2. FISH findings in squamous cell neoplastic nuclei. 3q
amplification.
doi:10.1371/journal.pone.0049689.g002
Figure 3. FISH findings in squamous cell neoplastic nuclei.
Nuclei with polysomy of chromosome 3 without 3q amplification
(polyploidy).
doi:10.1371/journal.pone.0049689.g003
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Discussion
In our study we observed that 1) absolute copy number of 3q
chromosomal region may harbour false positive interpretation of
3q amplification in squamous cell carcinoma; 3) correction for
chromosome 3 is important to identify true 3q amplification; 4) we
propose to consider a case ‘‘amplified for chromosome 3q’’ when
scoring $8 fluorescent signals; 5) false versus true 3q chromosomal
amplification in squamous cell lung carcinoma merit consideration
at light of emerging trials involving anti-PI3CA and SOX-2
targeted drugs.
Amplification of chromosome 3q has been described in
squamous neoplastic transformation from different sites [25].
Althought abnormalities on chromosome 3 and 3q has been
observed in minority percentages of lung adenocarcinomas with
different rates, in the squamous cell lung carcinomas amplifica-
tions is frequently detected at 3q24–q27 and represent a sensitive
genotypical marker of the squamous differentiation of lung
carcinomas [5,26,27,28,29,30,31].
In our study we highlighted the findings of three distinctive
clustered cytogenetic patterns and propose that correction for
chromosome 3 is critical for the determination of true 3q
amplification status. Today, there is no definitive consensus about
the optimal scoring system for assessing 3q amplification. Due to
the fact that the 3q region maps genes, such as SOX2 and PI3CA
genes, that may have potential role as novel targets for
therapeutics, we believe that the need in proposing guidelines
for appropriate evaluation of the 3q region status is important and
may have impact to different clinical levels. The absolute 3q copy
number or the alternative 3q/CEP3 ratio has to be evaluated
appropriately, when the predictivenesss to drug efficacy is going to
be determined. In our serie eight cases displayed true amplification
($8 fluorescent signals per nuclei) when corrected by chromosome
3. We validated these findings after wide genomic aCGH analysis.
False positive 3q amplification is present when absolute copy
number of 3q signals ranges from 3 to 7 per nuclei. Wide genomic
molecular profiling such as the array comparative genomic
hybridization technique may help in appropriate definition of
new cut-offs and validate standard ISH results and interpretation.
aCGH may distinguish gains of a chromosome due to polyploidy
or genetic instability versus true chromosomal amplification.
The chromosomal region spanning the 3q encounters many
interesting genes [32,33]. Several potential targets in the 3q
region, particularly at the 3q26–28 amplicon, have been identified
[6,34,35]. More recently, the knowledge of the key role of SOX2
oncogene which maps specifically to the distal part of chromosome
3q increases importance [19,20,21]. Wilbertz et al. found that
SOX2 amplification and upregulation are frequent events in
squamous cell carcinomas of the lung and are associated with
indicators of favorable prognosis [36]. Hussenet et al. highlighted
the recurrent SOX2 activation and its necessary role for squamous
neoplastic cell survival in squamous cell carcinoma [37].
At routinely laboratory level, fluorescence in situ hybridization
(FISH) on formalin-fixed, paraffin-embedded tissue is an increas-
ingly useful technique in the detection of many diagnostic
chromosomal abnormalities in different oncological fields [38].
Tonon et al. observed and highlighted different degree of gains
of chromosomes/genes in term of magnitude such as focal copy
number alterations, such as five genes gained in lung carcinomas
and others recurrent copy number alterations including high-
amplitude amplifications [39]. McCaughan et al. observed in a
subset of squamous lung carcinomas that progression of high-
grade preinvasive disease is associated with incremental amplifi-
cation of SOX2 and concluded that progressive 3q amplification is
present in the evolution of preinvasive squamous cell carcinoma.
Authors proposed the SOX2 gene as a key drug target of this
dynamic process [8]. Pelosi et al. focused their study on
preneoplastic/preinvasive squamous cell proliferations and early-
stage invasive carcinomas of the lung. 3q26 amplification and
polysomy of chromosome 3 were confined to malignant samples,
with 37% of invasive squamous cell carcinomas, and 27% of
severe dysplasias/in situ carcinomas showing these chromosomal
abnormalities [40].
The PI3K gene also set in the 3q chromosomal region. There
are ample genetic and laboratory studies that suggest the PI3K–
Akt pathway is vital to the growth and survival of cancer cells [41].
Inhibitors targeting this pathway are entering the clinic at a rapid
pace and the therapeutic potential of drugs targeting PI3K–Akt
signalling for the treatment of cancer is under deep consideration
[41]. Targeting PI3K gene in squamous cell carcinoma with 3q
amplification may be rationale-based promising trials.
In our study we did not observe relevant differences in term of
magnitude of genome gains when analyzing findings from
Figure 4. Squamous lung cell carcinoma. FISH scoring clustered into three groups after matching aCGH validation analysis. Notably, cases
showing from 3 to 7 fluorescent signals displayed no 3q amplification after aCGH analysis, thus showing false 3q amplification by FISH. Cases showing
$8 fluorescent signals displayed at aCGH analysis true 3q amplification.
doi:10.1371/journal.pone.0049689.g004
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oligonucleotide probes spanning the SOX2 and PI3CA chromo-
somal regions.
The clinical impact of the multifaceted genotypic abnormalities,
observed in the actual study, merits further investigation. We
evidenced that absolute enumeration of chromosomal copies is
challenging and the absence of analytical standardisation may
limit pre-clinical and clinical studies focusing on the predictiveness
of biomarkers mapping on the 3q region. False versus true 3q
chromosomal amplification in squamous cell lung carcinoma are
observed and its impact to trials involving anti-PI3K and -SOX2
targeted drugs is a direct consequence. Correction for chromo-
some 3 is critical for the determination of true 3q amplification
status: the definition of a detailed scoring system and a consensus is
mandatory.
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